For example, selective KCC1 or KCC3 antagonists would be suitable for the therapy of sickle cell anaemia, to prevent overactive transporters from dehydrating erythrocytes and contributing to HbS polymerization (Brown et␣al,2015). Here, SLC12A6 is linked to sickle cell disease.